Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company ...

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and ...

AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected ...

Since Friday, Morphic Therapeutic MORF shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. INDIANAPOLIS — Indianapolis-based Eli Lilly ...

Johnson & Johnson’s Janssen subsidiary has terminated its research collaboration and option agreement with Morphic Therapeutic, the company announced in a filing with the Securities and Exchange ...

Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and induced a lasting anti-tumor effect “These new data, in multiple well characterized ...